Drug NSAIDs DMARDs Opioids Steroids Substrate Inhibitor Inducer
Aspirine X       2C8, 2C9   2C19
Diclofenac X       2C8, 2C9, 2C19, 3A4, 2C8, 2C9, 3A4  
Ibuprofen X       2C8, 2C9, 2C19 2C9  
Indometacine X       2C9, 2C19 2C9, 2C19  
Ketoprofen X         2C9, 2C10  
Metamizol X           2B6, 3A4
Naproxen X       1A2, 2C8, 2C9    
Oxaprozin X       2C9    
Paracetamol X       1A1, 1A2, 2A6, 2C8, 2C9, 2D6, 2E1, 3A4 3A4 2D6, 2E1, 3A4/5
Phenylbutazon X       2C9   3A4
Piroxicam X       2C9 2C9  
Betamethasone       X 19A 3A4 19A
Hydrocortisone       X 3A4 3A4 2C8, 3A4
Prednisone       X 3A4 3A4 1A1, 1A2, 3A4
Codeine     X   2D6, 3A4 2D6  
Fentanyl     X   3A4 3A4  
Morphin     X   2C8, 3A4    
Tramadol     X   2B6, 2D6, 3A4 2D6, 3A4  
Chloroquine   X     1A1, 2C8, 2D6, 3A4 2D6  
Cyclosporine   X     3A4 2C19, 2D6, 3A4  
Hydochloroquine   X       2D6  
Leflunomide   X     2C8, 2C9 2C8, 2C9  
Additional administration of antibiotics in the therapy of PD could influence the metabolism of the other drugs administered for RA therapy. Potent antibiotic agents against periodontal bacterial pathogens are listed in Table
Table 1: Drugs in the therapy of RA with CYP metabolism. Involved CYPs are ordered in mode of action (substrate, inhibitor, inducer) and references are given in supplementary material.